Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04881045 · ClinicalTrials.gov registry record · Phase 1
Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT04881045 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 29 participants.
The verdict
NCT04881045, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic and potential clinical benefit of PF-07257876, a CD47-PD-L1 bispecific antibody, in participants with selected advanced or metastatic tumors for whom no standard therapy is available. The study contains 2 parts, single agent Dose Escalation (Part 1) to determine the recommended dose of PF-07257876, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose.
Interventions
- BIOLOGICAL PF-07257876
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-08-18 |
| Est. Completion | 2023-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04881045
The ClinicalTrials.gov registry entry for NCT04881045 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-07257876 is the first listed.
NCT04881045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04881045 about?
NCT04881045 is a clinical study titled "Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.". This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic and potential clinical benefit of PF-07257876, a CD47-PD-L1 bispecific antibody, in participants with selected advance...
What is the current status of trial NCT04881045?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2021-08-18. Estimated completion is 2023-10-24.
What interventions are being tested in trial NCT04881045?
The interventions under investigation include: PF-07257876 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04881045?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.